At the European Cell and Gene Therapy Summit 2024, confidence in the sector’s maturity and progress was evident, highlighted ...

ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...

California-based Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration ...

Eli Lilly has announced a strategic collaboration with UK government departments to address population health challenges, ...

A staggering 800% increase in licensing agreement deal values for messenger ribonucleic acid (mRNA)-based innovator ...

The American Lung Association Research Institute has announced a $22 million investment in 2024 to fund 139 research grants ...

Netherlands-based venture capital firm Forbion has raised over €2 billion ($2.2 billion) across its newest funds, bringing ...

Eli Lilly (NYSE: LLY) has partnered with the UK government, investing £279 million ($340 million) to address public health ...

The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...

TRIANA Biomedicines has entered into a strategic collaboration and licensing agreement with US pharma giant Pfizer to ...

Nuclera has raised $75 million, led by Elevage Medical Technologies, to commercialize its eProtein Discovery system. The ...

Johnson & Johnson has announced positive Phase II/III trial results for nipocalimab in generalized myasthenia gravis (gMG). The drug showed significant IgG reduction and sustained disease control.